BrainStorm scraps initial access to NurOwn® for amyotrophic lateral sclerosis

Written by Sharon Salt, Editor

BrainStorm Cell Therapeutics Inc. (NY, USA; Petach Tikva, Israel), a leading developer of adult stem cell technologies for neurodegenerative diseases, have announced that after careful consideration of the newly enacted ‘Right to Try’ (RTT) Act, it will not make NurOwn® available under this legislation at this time. However, the company will continue to focus on efforts to complete the ongoing NurOwn Phase III study, which is evaluating the efficacy and safety of repeated administration of NurOwn (autologous mesenchymal stem cells secreting neurotrophic factors), as quickly as possible with the goal of bringing a meaningful treatment option to amyotrophic lateral sclerosis...

To view the full article, please register now for access

It's completely free